| Followers | 59 |
| Posts | 7590 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Wednesday, January 05, 2022 11:25:04 PM
Xblkbk, I see this as a "catch-22." A BO cannot happen until AMRN proves
Vascepa is a success in Europe, Canada, China. Yet, only a BP is capable
of delivering that success. I don't know what will change this seeming
impasse. Maybe a Marjac win? Perhaps Pfizer has their own game plan
in mind (whatever that may be.) Perhaps there will be an unexpected
catalyst. Meanwhile, the exclusivity clock ticks away for Europe and
China. My hope is that KM is setting AMRN up to be able to extract the
highest takeover price possible. (Perhaps by getting country approvals
accomplished and negotiating prices to insure value for an acquirer.)
I still wonder how Vascepa will be priced in China. (Must be high enough
to insure a profit for both Edding and AMRN yet low enough so as not to
discourage sales as well be priced in a way to get China to cover some
of the cost. Pfizer sells a couple billion in Lipitor in China, working
with Edding to do a mutually beneficial deal seems like no brainer.
Yet, the share price of AMRN reflects none of this.
Vascepa is a success in Europe, Canada, China. Yet, only a BP is capable
of delivering that success. I don't know what will change this seeming
impasse. Maybe a Marjac win? Perhaps Pfizer has their own game plan
in mind (whatever that may be.) Perhaps there will be an unexpected
catalyst. Meanwhile, the exclusivity clock ticks away for Europe and
China. My hope is that KM is setting AMRN up to be able to extract the
highest takeover price possible. (Perhaps by getting country approvals
accomplished and negotiating prices to insure value for an acquirer.)
I still wonder how Vascepa will be priced in China. (Must be high enough
to insure a profit for both Edding and AMRN yet low enough so as not to
discourage sales as well be priced in a way to get China to cover some
of the cost. Pfizer sells a couple billion in Lipitor in China, working
with Edding to do a mutually beneficial deal seems like no brainer.
Yet, the share price of AMRN reflects none of this.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
